Details

SARS-CoV-2 vaccination and clinical presentation of COVID-19 in patients hospitalized during the delta- and omicron-predominant periods
ID Stupica, Daša (Author), ID Collinet-Adler, Stefan (Author), ID Kejžar, Nataša (Author), ID Poljak, Mario (Author), ID Štamol, Tina (Author)

.pdfPDF - Presentation file, Download (1020,37 KB)
MD5: 3DD10DDDAA9E0C6BE24FD3D7D6EDC9A8
URLURL - Source URL, Visit https://www.mdpi.com/2077-0383/12/3/961 This link opens in a new window

Abstract
Evidence suggests that monovalent vaccine formulations are less effective against the Omicron SARS-CoV-2 than against previous variants. In this retrospective cohort study of hospitalized adults with PCR-confirmed COVID-19 during the Delta (October-November 2021) and Omicron (January-April 2022) variant predominant periods in Slovenia, we assessed the association between primary vaccination against SARS-CoV-2 and progression to critically severe disease (mechanical ventilation or death). Compared with the 529 patients hospitalized for acute COVID-19 during the Delta period (median age 65 years; 58.4% men), the 407 patients hospitalized during the Omicron period (median age 75 years; 50.6% men) were older, more often resided in long-term care facilities, and had higher Charlson comorbidity index scores. After adjusting for age, sex, the Charlson comorbidity index, the presence of immunocompromising conditions, and vaccination status, the patients admitted during the Omicron period had comparable odds of progressing to critically severe disease to those admitted during the Delta period. The 334/936 (35.7%) patients completing at least primary vaccination had lower odds of progression to critically severe disease and shorter hospital stay than unvaccinated patients; however, the protective effect of vaccination was less pronounced during the Omicron than during the Delta period. Although the Omicron variant appeared to better evade immunity induced by monovalent vaccines than the Delta variant, vaccination against SARS-CoV-2 remained an effective intervention to decrease morbidity and mortality in COVID-19 patients infected with the Omicron variant.

Language:English
Keywords:COVID-19 vaccine, SARS-CoV-2 antibodies, vaccine breakthrough
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2023
Number of pages:13 str.
Numbering:Vol. 12, iss. 3
PID:20.500.12556/RUL-189849 This link opens in a new window
UDC:616.9
ISSN on article:2077-0383
DOI:10.3390/jcm12030961 This link opens in a new window
COBISS.SI-ID:141887491 This link opens in a new window
Publication date in RUL:19.10.2026
Views:61
Downloads:11
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Journal of clinical medicine
Shortened title:J. clin. med.
Publisher:MDPI
ISSN:2077-0383
COBISS.SI-ID:5405759 This link opens in a new window

Secondary language

Language:Slovenian
Keywords:cepivo za covid-19, protitelesa SARS-CoV-2, preboj cepiva

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P3-0154
Name:Metodologija za analizo podatkov v medicini

Funder:University Medical Centre Ljubljana, Slovenia
Project number:TP20220153

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back